Testosterone replacement therapy (TRT) is linked to a significantly lower risk of major CV events in men with secondary hypogonadism.

The narrow FDA labeling makes it so that only a minority of men who could benefit from treatment are considered ‘on-label’ treatment, and many physicians are reluctant to ...

At an FDA discussion of testosterone replacement therapy, a top official called for special health centers to address a ...

New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and/or when you make a purchase. Accessing Testosterone Replacement Therapy shouldn’t make you ...

Male hypogonadism means your body isn’t making enough testosterone, the hormone that plays a role in drive, energy, and muscle strength. Primary hypogonadism starts … ...

This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once … ...